Oxford BioMedica PLC Seeks To Raise Up To 30 Million

LONDON, Nov 2 (Reuters) - Britain’s Oxford Biomedica (OXB.L: Quote, Profile, Research) said on Wednesday it planned to raise up to 30 million pounds ($53 million)in a placing and open offer of its shares to fund final stage clinical trials of its key drug, TroVax for cancer.

MORE ON THIS TOPIC